We have developed substantial expertise in the field of infectious diseases and are committed to contributing to the eradication, elimination and control of certain infectious diseases.
Because life is a health journey, we work with international organizations (Gavi, the Vaccine Alliance, WHO and UNICEF) towards a world where vaccination could ensure that people no longer suffer from a preventable disease. We are committed to providing quality vaccines at affordable prices.
We are a longstanding partner of the Global Polio Eradication Initiative (GPEI) providing oral polio vaccines since 1999 and injectable polio vaccines since 2014 with the aim of eradicating the disease.
In 2016, we delivered 42 million doses of IPV standalone to UNICEF for GAVI countries.
Watch the video
Malaria is one of the most deadly infectious diseases in the world. According to the World Health Organization, there were approximately 214 million cases and 438,000 deaths due to malaria in 2015, mostly among African children. In Africa, one child dies of malaria every two minutes.
As a health journey partner, we supply our ASAQ Winthrop® drug, a fixed dose combination of artesunate-amodiaquine developed in partnership with the Drugs for Neglected Diseases Initiative (DNDi), and for which we did not seek patent protection, at preferential prices. Since its launch in 2007, ASAQ Winthrop® has enabled the treatment of over 400 million malaria attacks, including more than 43 million in 2016.
We also collaborate with national malaria control programs, ministries of Education and NGOs, and developed the Schoolchildren Against Malaria program, in order to promote prevention in schools in sub-Saharan Africa. In 2016, the program was still active in Gabon and Mozambique and close to 10,000 children and school staff benefited from awareness programs. In 2017, additional awareness initiatives took place in Cameroon, Guinea and Togo.
Learn more on malaria
Sleeping sickness threatens millions of people in sub-Saharan Africa. This disease is fatal if not treated.
Because we are a health journey partner, thanks to our partnership with the WHO which started in 2001, 34 million people have been screened for sleeping sickness and close to 200 000 patients have been treated. Moreover, since 2009, we entered into an innovative partnership with the Drugs for Neglected Diseases Initiative (DNDi) for the development of fexinidazole, oral monotherapy for all stages of the disease. DNDi has carried out clinical testing and we are responsible for industrial development, production and regulatory submission. An oral monotherapy for sleeping sickness can contribute to simplifying treatment by avoiding systematic hospitalization and removing the need of lumbar punctures for patients.
The Phase II/III clinical trials completed in the Democratic Republic of Congo and Central African Republic achieved the primary endpoints, enabling us to pursue submission for approval by health authorities. Fexinidazole could represent a therapeutic breakthrough which will support sustainable elimination efforts as set out by the World Health Organization’s roadmap for 2020.
Learn more on sleeping sickness